Skip to content
Triangle logo TriangleGet started
← Study library

NCT01139775 · REGISTRY CONDITION SEARCH

A Study in Non Small Cell Lung Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2018-05-18

LY2603618 is a selective inhibitor of the deoxyribonucleic acid (DNA) damage checkpoint kinase 1 (CHK1). It was being developed as a chemotherapeutic-enhancing agent in the treatment of cancer. Phase 1 studies have shown the feasibility of combining LY2603618 with either gemcitabine or pemetrexed. The objective of this study was to find the dose of LY2603618 that can be safely combined with standard doses of pemetrexed and cisplatin and to test if this triplet offered a significant improvement in progression-free survival (PFS) in participants with Stage IV nonsquamous non-small cell lung cancer (NSCLC) in the first-line of palliative treatment.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Phase 2: Progression-Free Survival Time

→

outcome · POSTED

Phase 1: Recommended Phase 2 Dose of LY2603618

→

outcome · POSTED

Phase 2: Overall Survival

→

outcome · POSTED

Phase 2: Overall Tumor Response Rate: Percentage of Participants Who Achieved a Confirmed Best Response of Completed Response (CR) or Partial Response (PR)

→

outcome · POSTED

Phase 2: Change in Tumor Size

→

outcome · POSTED

Phase 1: Pharmacokinetic: Maximum Plasma Concentration (Cmax) (LY2603618)

→

outcome · POSTED

Phase 1: Pharmacokinetic: Cmax (Pemetrexed and Cisplatin)

→

outcome · POSTED

Phase 1: Pharmacokinetic: Area Under the Plasma Concentration Versus Time Curve (AUC) (LY2603618)

→

outcome · POSTED

Phase 1: Pharmacokinetic: AUC (Pemetrexed and Cisplatin)

→

outcome · POSTED

Phase 2: Pharmacokinetic: Cmax (LY2603618)

→

outcome · POSTED

Phase 2: Pharmacokinetic: AUC (LY2603618)

→

outcome · POSTED

Phase 2: Change From Baseline to Long-term Follow up in Lung Cancer Symptom Scale (LCSS)

→

outcome · POSTED

Phase 1: Document Any Antitumor Activity Per Radiological Scans and/or Tumor Markers

→

outcome · POSTED

Deaths

→

outcome · POSTED

Phase 2: Proportion of Participants Receiving Maintenance Therapy

→

outcome · POSTED

Phase 2: Clinical Benefit Rate: Percentage of Participant Who Achieved a Response of Stable Disease (SD), Partial Response (PR), or Complete Response (CR)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Phase 1 portion: * Participants with a cytologic or histologic diagnosis of nonsquamous NSCLC that is classified as Stage IV according to the 7th edition of the American Joint Committee on Cancer (AJCC) classification and for whom the combination of pemetrexed and cisplatin is deemed to be appropriate * Participants with histologic or cytologic diagnosis of malignant mesothelioma that is unresectable * Participants with histologic or cytologic diagnoses of advanced or metastatic solid tumors who are not candidates for any standard therapy and for whom the combination with pemetrexed and cisplatin is deemed to be appropriate * Phase 2 portion: * Have a histological diagnosis of NSCLC other than predominantly squamous cell histology that is classified as Stage IV according to the 7th edition of the AJCC classification * Eligible for a first line of palliative treatment with a platinum doublet * Have archived or fresh tumor tissue (not cytology) * Phase 1 participants can have measurable or nonmeasurable disease. Phase 2 participants must have at least 1 measurable lesion according to Investigational New Drug (Response Evaluation Criteria in Solid Tumors \[RECIST\], v1.1) definitions. Tumor lesions located in a previously irradiated area can be considered measurable if they are new or if have shown unequivocal progression. * Have a performance status ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale * Have adequate hematologic, hepatic, and renal organ function * Prior radiation therapy for treatment of cancer is allowed to \<25% of the bone marrow, and participants must have recovered from the acute toxic effects of their treatment prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 4 weeks before study entry * For women: Must be surgically sterile, postmenopausal, or compliant with a highly reliable contraceptive method (failure rate \<1%) during and for 6 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment and must not be breast-feeding. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period Exclusion Criteria: * Have serious preexisting medical conditions or serious concomitant systemic disorders that would compromise the safety of the participant or his/her ability to complete the study, at the discretion of the investigator (for example, unstable angina pectoris or uncontrolled diabetes mellitus). Special attention should be paid to kidney and heart conditions that may be worsened with cisplatin treatment or hydration * Have central nervous system (CNS) metastases (unless the participant has completed successful local therapy for CNS metastases and has been off corticosteroids for at least 4 weeks before starting study therapy). A screening computed tomography scan or magnetic resonance imaging before enrollment in the absence of a clinical suspicion of brain metastases is not required. * Have current active infection that would, in the opinion of the investigator, compromise the participant's ability to tolerate therapy * Have known allergy to pemetrexed, cisplatin, LY2603618, or any ingredient of pemetrexed, cisplatin, or LY2603618 * Have clinically significant (by physical exam) third-space fluid collections; for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry * Participants taking non-steroidal anti-inflammatory drugs who cannot interrupt the treatment appropriately according to the guidelines * Have received a recent yellow-fever vaccination (within 28 days of enrollment) or are receiving concurrent yellow-fever vaccination * Phase 1 portion: * Have received more than 2 previous lines of chemotherapy for the advanced/metastatic disease * Have received more than 6 cycles of therapy containing an alkylating agent
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Cycle 1-2 (21-day cycle): Day 1: pemetrexed 500 milligrams per meter square (mg/m\^2) + cisplatin 75 mg/m\^2 Day 2: LY2603618 at 130-275 milligrams (mg) After 2 cycles, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
    intervention Names
    1. Drug: Pemetrexed
    2. Drug: Cisplatin
    3. Drug: LY2603618
    label
    Phase 1: LY2603618 130 to 275 mg
    type
    EXPERIMENTAL
  2. description
    Cycles 1-4 (21-day cycle): Before 25 Oct 2012: Day 1: pemetrexed 500 mg/m\^2 + cisplatin 75 mg/m\^2 Day 2: LY2603618 dose from phase 1 portion of trial After 25 Oct 2012: Day 1: pemetrexed 500 mg/m\^2 + cisplatin 75 mg/m\^2 After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met. Maintenance Therapy Experimental Arm (every 21 days): Before 25 Oct 2012: Day 1: pemetrexed 500 mg/m\^2 Day 2: LY2603618 dose determined from phase 1 After 25 Oct 2012: Day 1: pemetrexed 500 mg/m\^2 If, as of 25 Oct 2012, participant was in maintenance therapy and randomized to the experimental arm, the participant is eligible to continue with pemetrexed (Day 1)/LY2603618 (Day 2) therapy if the investigator deems it is in the best interest of the participant and the participant consents.
    intervention Names
    1. Drug: Pemetrexed
    2. Drug: Cisplatin
    3. Drug: LY2603618
    label
    Phase 2: Pemetrexed + Cisplatin + LY2603618
    type
    EXPERIMENTAL
  3. description
    Cycle 1-4 (21-day cycle): Day 1: pemetrexed 500 mg/m\^2 + cisplatin 75 mg/m\^2 After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met. Maintenance Therapy Comparator Arm: Phase 2 (every 21 days): Day 1: pemetrexed 500 mg/m\^2
    intervention Names
    1. Drug: Pemetrexed
    2. Drug: Cisplatin
    label
    Phase 2: Pemetrexed + Cisplatin
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Phase 1: LY2603618 130 to 275 mg
    2. Phase 2: Pemetrexed + Cisplatin
    3. Phase 2: Pemetrexed + Cisplatin + LY2603618
    description
    Administered intravenously as a continuous 10-minute infusion
    name
    Pemetrexed
    type
    DRUG
  2. arm Group Labels
    1. Phase 1: LY2603618 130 to 275 mg
    2. Phase 2: Pemetrexed + Cisplatin
    3. Phase 2: Pemetrexed + Cisplatin + LY2603618
    description
    Administered intravenously as a continuous 1-hour infusion
    name
    Cisplatin
    type
    DRUG
  3. arm Group Labels
    1. Phase 1: LY2603618 130 to 275 mg
    2. Phase 2: Pemetrexed + Cisplatin + LY2603618
    description
    Administered intravenously as a continuous 1-hour infusion
    name
    LY2603618
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
76
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    Deaths that occurred during the study are presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
    measure
    Deaths
    time Frame
    Randomization through 12 months after the last participant was randomized
primary Outcomes
  1. description
    Progression-free survival (PFS) time is defined as the time from the date of randomization to the first date of documented objective progressive disease (PD) or death from any cause. For participants who were not known to have had objective PD as of the data inclusion cut-off date for a particular analysis, PFS was censored at the date of the last objective progression-free disease assessments. For participants who took any subsequent systemic anticancer therapy prior to progression, PFS was censored at the date of the last objective progression-free disease assessment prior to the start date of any subsequent systemic anticancer therapy. PFS time was summarized using Kaplan-Meier estimates.
    measure
    Phase 2: Progression-Free Survival Time
    time Frame
    Randomization up to first date of PD or death from any cause (up to 6 months after the last participant entered treatment)
  2. description
    The recommended Phase 2 dose for LY2603618 when administered approximately 24 hours after pemetrexed and cisplatin was based on the maximum tolerated dose (MTD) and achievement of predefined LY2603618 plasma systemic exposures targets (area under the LY2603618 plasma concentration versus time curve from time zero to infinity \[AUC(0-∞)\] \>21,000 nanogram\*hour/milliliter \[ng\*h/mL\] and maximum LY2603618 plasma concentration \[Cmax\] \>2000 nanograms/milliliter \[ng/mL\]).
    measure
    Phase 1: Recommended Phase 2 Dose of LY2603618
    time Frame
    Time of first dose to last dose
secondary Outcomes
  1. description
    Overall survival (OS) time is defined as the time from the date of randomization to the date of death from any cause. For participants not known to have died as of the data cut-off date, OS time was censored at the last contact date the participant was known to be alive prior to the data cut-off date. OS was summarized using Kaplan-Meier estimates.
    measure
    Phase 2: Overall Survival
    time Frame
    Randomization to the date of death from any cause through the time of study discontinuation (approximately 12 months after last participant was randomized)
  2. description
    Overall response rate is the best response of CR or PR as classified by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST, v1.1) guidelines. CR is defined as the disappearance of all target and non-target lesions, normalization of tumor marker level of non-target lesions, and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm). PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
    measure
    Phase 2: Overall Tumor Response Rate: Percentage of Participants Who Achieved a Confirmed Best Response of Completed Response (CR) or Partial Response (PR)
    time Frame
    Randomization until date of disease progression (up to 6 months after the last participant was randomized)
  3. description
    Change in tumor size was based on tumor measurements collected according to RECIST, v1.1 guidelines. Tumor size is the sum of the tumor measurements (longest diameters) of target lesions at each tumor evaluation. Change in tumor size was defined as the change in log tumor size from baseline evaluation to the evaluation at the end of Cycle 2.
    measure
    Phase 2: Change in Tumor Size
    time Frame
    Baseline, end of Cycle 2
  4. description
    Cmax is reported for each LY2603618 dose level on Cycle 1 /Day 2 and Cycle 2 /Day 2. The number of pharmacokinetic observations (n) used in the analysis is presented for each dose level and time point.
    measure
    Phase 1: Pharmacokinetic: Maximum Plasma Concentration (Cmax) (LY2603618)
    time Frame
    Cycle 1/Day 2 - immediately prior to end of LY2603618 infusion, and 1, 3, 6, 24, 48, 72, and 144 hours postdose; Cycle 2/Day 2 - predose, immediately prior to end of LY2603618 infusion, and 1, 3, 6, 24, 48, 72, and 144 hours postdose
  5. description
    Cmax for pemetrexed and total platinum (t-platinum) from cisplatin is reported. The number of pharmacokinetic observations (n) used in the analysis is presented for each drug.
    measure
    Phase 1: Pharmacokinetic: Cmax (Pemetrexed and Cisplatin)
    time Frame
    Pemetrexed: Cycle 1/Day 1 - immediately prior to end of pemetrexed infusion and 1, 2, 6 and 24 hours postdose. Cisplatin: Cycle 1/Day 1 - immediately prior to end of cisplatin infusion and 0.5, 1, 2, 6, 24, 72, 96, and 168 hours postdose.
  6. description
    AUC from time zero to 24 hours (AUC\[0-24\]), AUC from time zero to the last time point with a measurable concentration (AUC\[0-tlast\]), and AUC from time zero to infinity (AUC\[0-∞\]) values are reported for each LY2603618 dose level on Cycle 1 /Day 2 and Cycle 2 /Day 2. The number of pharmacokinetic observations (n) used in the analysis is presented for each dose level and time point.
    measure
    Phase 1: Pharmacokinetic: Area Under the Plasma Concentration Versus Time Curve (AUC) (LY2603618)
    time Frame
    Cycle 1/Day 2 - immediately prior to end of LY2603618 infusion and 1, 3, 6, 24, 48, 72, and 144 hours postdose; Cycle 2/Day 2 - predose, immediately prior to end of LY2603618 infusion, and 1, 3, 6, 24, 48, 72, and 144 hours postdose
  7. description
    AUC(0-tlast) and AUC(0-∞) values are reported for pemetrexed and t-platinum from cisplatin. The number of pharmacokinetic observations (n) used in the analysis is presented for each drug.
    measure
    Phase 1: Pharmacokinetic: AUC (Pemetrexed and Cisplatin)
    time Frame
    Pemetrexed: Cycle 1/Day 1 - immediately prior to end of pemetrexed infusion and 1, 2, 6 and 24 hours postdose. Cisplatin: Cycle 1/Day 1 - immediately prior to end of cisplatin infusion and 0.5, 1, 2, 6, 24, 72, 96, and 168 hours postdose.
  8. measure
    Phase 2: Pharmacokinetic: Cmax (LY2603618)
    time Frame
    Cycle 1/Day 2 - predose, immediately prior to the end of the LY2603618 infusion, and 2-6, 24-48, and 72-96 hours postdose
  9. description
    AUC (0-24), AUC(0-tlast), and AUC(0-∞) values are reported for LY2603618. The number of pharmacokinetic observations (n) used in the analysis is presented.
    measure
    Phase 2: Pharmacokinetic: AUC (LY2603618)
    time Frame
    Cycle 1/Day 2 - predose, immediately prior to the end of the LY2603618 infusion, and 2-6, 24-48, and 72-96 hours postdose
  10. description
    Health-related quality of life and participant symptoms were assessed using the LCSS (patient scale). However, improper implementation of questionnaires at the site level reduced the sponsor's ability to accurately evaluate the impacted data. Therefore, the LCSS data should be interpreted with caution. The LCSS is a 9-item questionnaire. Six questions are symptom-specific measures for lung cancer (appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items describe total symptomatic distress, activity status, and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-milliliter (mm) lines. Scores range from 0 (for best outcome) to 100 (for worst outcome). The Average Symptom Burden Index (ASBI) was calculated as the mean of 6 symptom-specific questions from the LCSS. The total LCSS score was calculated as the mean of 9 questions from the LCSS.
    measure
    Phase 2: Change From Baseline to Long-term Follow up in Lung Cancer Symptom Scale (LCSS)
    time Frame
    Randomization to the end of study (approximately 12 months after the last participant entered treatment)
  11. description
    Overall response rate is presented. Overall response rate is defined as the percentage of participants with a best response of CR or PR as classified by the investigators according to RECIST, v1.1 criteria. CR is defined as the disappearance of all target and non-target lesions, normalization of tumor marker level of non-target lesions, and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
    measure
    Phase 1: Document Any Antitumor Activity Per Radiological Scans and/or Tumor Markers
    time Frame
    Baseline through end of Phase 1
  12. measure
    Phase 2: Proportion of Participants Receiving Maintenance Therapy
    time Frame
    Cycle 5
Full study description
brief Summary
LY2603618 is a selective inhibitor of the deoxyribonucleic acid (DNA) damage checkpoint kinase 1 (CHK1). It was being developed as a chemotherapeutic-enhancing agent in the treatment of cancer. Phase 1 studies have shown the feasibility of combining LY2603618 with either gemcitabine or pemetrexed. The objective of this study was to find the dose of LY2603618 that can be safely combined with standard doses of pemetrexed and cisplatin and to test if this triplet offered a significant improvement in progression-free survival (PFS) in participants with Stage IV nonsquamous non-small cell lung cancer (NSCLC) in the first-line of palliative treatment.
Source references
references
  1. citation
    Wehler T, Thomas M, Schumann C, Bosch-Barrera J, Vinolas Segarra N, Dickgreber NJ, Dalhoff K, Sebastian M, Corral Jaime J, Alonso M, Hynes SM, Lin J, Hurt K, Bence Lin A, Calvo E, Paz-Ares L. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer. 2017 Jun;108:212-216. doi: 10.1016/j.lungcan.2017.03.001. Epub 2017 Mar 6.
    pmid
    28625637
    type
    DERIVED
  2. citation
    Calvo E, Chen VJ, Marshall M, Ohnmacht U, Hynes SM, Kumm E, Diaz HB, Barnard D, Merzoug FF, Huber L, Kays L, Iversen P, Calles A, Voss B, Lin AB, Dickgreber N, Wehler T, Sebastian M. Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs. 2014 Oct;32(5):955-68. doi: 10.1007/s10637-014-0114-5. Epub 2014 Jun 20.
    pmid
    24942404
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-c1e14a37e630fa7b478a
      requested nct id
      NCT01139775
      primary nct id
      NCT01139775
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
      payload sha256
      94129e3159598a29ad607a842bb2aa156312c0ed16ae28cf437fe002aa00a1f7
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-c1e14a37e630fa7b478a
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01139775
      occurrences
      1. context exact
        NCT01139775
        end
        11
        exact text
        NCT01139775
        start
        0
      offset unit
      unicode_code_points
      query cond
      Malignant Mesothelioma
      query disease state id
      ds-malignant-mesothelioma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-malignant-mesothelioma-000.json
      source file sha256
      0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
      source json pointer
      /studies/24/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      3ee1beb708640cad6d056466a85669bcf48b24341c3374bc6fe9680a2cd3d516

    Preserved source evidence · Not medical advice